Christine Garnett

Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase

Börje Darpö, Charles Benson, Corina Dota et al. · Clinical Pharmacology & Therapeutics · 2015 · 176 citations · Full text

Population Pharmacokinetic and Concentration-QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies

Jeffry Florian, Christoffer W. Tornøe, Richard C. Brundage et al. · The Journal of Clinical Pharmacology · 2011 · 168 citations

Population Pharmacokinetic, Pharmacokinetic Modeling, Pharmacological Study +12

Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

Katherine A. Thornton, Geoffrey Kim, V. Ellen Maher et al. · Clinical Cancer Research · 2012 · 147 citations

Caprelsa Tablets, U.s. Food, Medicine +11

Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions

Joo Yeon Lee, Christine Garnett, Jogarao Gobburu et al. · Clinical Pharmacokinetics · 2011 · 146 citations

Drug Safety, Labelling Decisions, New Drug Approval +9

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

Albert Deisseroth, Edvardas Kaminskas, Joseph A. Grillo et al. · Clinical Cancer Research · 2012 · 143 citations

Hematological Malignancy, Antifibrotic Therapy, Oncology +14